» Articles » PMID: 27872100

Regeneration of CD8αβ T Cells from T-cell-Derived IPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity

Overview
Journal Cancer Res
Specialty Oncology
Date 2016 Nov 23
PMID 27872100
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Although adoptive transfer of cytotoxic T lymphocytes (CTL) offer a promising cancer therapeutic direction, the generation of antigen-specific CTL from patients has faced difficulty in efficient expansion in ex vivo culture. To resolve this issue, several groups have proposed that induced pluripotent stem cell technology be applied for the expansion of antigen-specific CTL, which retain expression of the same T-cell receptor as original CTL. However, in these previous studies, the regenerated CTL are mostly of the CD8αα innate type and have less antigen-specific cytotoxic activity than primary CTL. Here we report that, by stimulating purified iPSC-derived CD4/CD8 double-positive cells with anti-CD3 antibody, T cells expressing CD8αβ were generated and exhibited improved antigen-specific cytotoxicity compared with CD8αα CTL. Failure of CD8αβ T-cell production using the previous method was found to be due to killing of double-positive cells by the double-negative cells in the mixed cultures. We found that WT1 tumor antigen-specific CTL regenerated by this method prolonged the survival of mice bearing WT1-expressing leukemic cells. Implementation of our methods may offer a useful clinical tool. Cancer Res; 76(23); 6839-50. ©2016 AACR.

Citing Articles

Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells.

Lindenbergh P, van der Stegen S Transfus Med Hemother. 2025; 52(1):27-41.

PMID: 39944411 PMC: 11813279. DOI: 10.1159/000540473.


Engineered Cellular Therapies for the Treatment of Thoracic Cancers.

Erickson S, Manning B, Kumar A, Patel M Cancers (Basel). 2025; 17(1.

PMID: 39796666 PMC: 11718842. DOI: 10.3390/cancers17010035.


Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.

Alidadi M, Barzgar H, Zaman M, Paevskaya O, Metanat Y, Khodabandehloo E Front Cell Dev Biol. 2024; 12:1491282.

PMID: 39624236 PMC: 11609223. DOI: 10.3389/fcell.2024.1491282.


Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy.

Kurihara S, Ishikawa A, Kaneko S Inflamm Regen. 2024; 44(1):20.

PMID: 38637837 PMC: 11025212. DOI: 10.1186/s41232-024-00328-3.


Development of Immune Cell Therapy Using T Cells Generated from Pluripotent Stem Cells.

Kawamoto H, Masuda K, Nagano S Adv Exp Med Biol. 2024; 1444:207-217.

PMID: 38467982 DOI: 10.1007/978-981-99-9781-7_14.